as 02-05-2025 1:40pm EST
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | CHICAGO |
Market Cap: | 43.6M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 131.1K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.20 | EPS Growth: | N/A |
52 Week Low/High: | $1.44 - $36.00 | Next Earning Date: | 11-14-2024 |
Revenue: | $500,000 | Revenue Growth: | -97.70% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
XCUR Breaking Stock News: Dive into XCUR Ticker-Specific Updates for Smart Investing
Business Wire
14 days ago
Business Wire
a month ago
Business Wire
a month ago
Business Wire
3 months ago
Business Wire
5 months ago
Business Wire
5 months ago
Business Wire
5 months ago
Business Wire
6 months ago
The information presented on this page, "XCUR Exicure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.